Theravance Inc $26.47

down -0.66


17/4/2014 08:10 PM  |  NASDAQ : THRX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get THRX Trend Analysis - it has underperformed the S&P 500 by 26%

Partner Headlines

  1. Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational ...

    Benzinga
  2. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  3. Morgan Stanley Expects Theravance to Continue to Underperform Following ...

    Benzinga
  4. Top 2013 Drug Approvals: Pharma Stocks

    YCharts
  5. Positive data for asthma drug

    IBD
  6. Theravance, Glaxo COPD Drug Does Well In Asthma

    IBD
  7. Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, ...

    GuruFocus
  8. GlaxoSmithKline

    IBD
  9. US Stock Futures Signal Flat Start On Wall Street

    Benzinga
  10. Relvar Ellipta Approved in Japan for Treatment of Asthma

    Benzinga
  11. Glaxo, Theravance Confirm Positive CHMP Opinion for Relvar Ellipta

    Benzinga
  12. Glaxo, Theravance Confirms FDA Panel Has Recommended Approval for UMEC/VI ...

    Benzinga
  13. Theravance Reports Results from Phase 2B Study 0091 with TD-4208 for COPD, ...

    Benzinga
  14. Missed Klarman’s 47% Gainer? His Other Value Pick

    YCharts
  15. Seth Klarman's Top 5 Second Quarter Holdings

    GuruFocus
  16. Perrigo-Elan Merger Creates Unlikely Pharma Union

    IBD
  17. UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of March PADAC ...

    Benzinga
  18. Theravance to Offer $250 Million Convertible Subordinated Notes Due 2023

    Benzinga
  19. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  20. Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

    Benzinga
  21. Theravance Offers FDA Briefing Documents for Panel Meeting on VIBATIV(R)

    Benzinga
  22. Theravance Enters Agreement With Alfa Wassermann Worth Up To $53.5M

    Benzinga
  23. The Baupost Group's Favorite Stocks

    Benzinga
  24. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 24,682 Shares

    GuruFocus
  25. GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily ...

    Benzinga
  26. Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX

    GuruFocus
  27. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 60,000 Shares

    GuruFocus
  28. Theravance Inc. (THRX) CEO Rick E Winningham sells 75,749 Shares

    GuruFocus
  29. A Peek Into The Market Before The Trading Starts

    Benzinga
  30. GSK and Theravance Announce Regulatory Submissions for FF/VI in the US ...

    Benzinga
  31. Target, Amgen Among Stocks Hitting 52-Week Highs Wednesday

    FoxBusiness
  32. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  33. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs Monday

    FoxBusiness
  34. Health Care Sector Wrap

    FoxBusiness
  35. Health Care Sector Wrap

    FoxBusiness
  36. GSK and Theravance Announce Positive Results From Four Pivotal Phase III ...

    Benzinga
  37. Theravance Inc. Reports Operating Results (10-K)

    GuruFocus
  38. UPDATE: Morgan Stanley Initiates Underweight, $12 PT on Theravance

    Benzinga
  39. Morgan Stanley Initiates Theravance at Underweight

    Benzinga
  40. Afternoon Movers; Markets Moved Higher

    Benzinga
  41. Morning Market Losers

    Benzinga
  42. From Earlier: GSK and Theravance Announce Initial Outcomes From Pivotal ...

    Benzinga
  43. UPDATE: Piper Jaffray Raises Price Target on Theravance to $35

    Benzinga
  44. Piper Jaffray Raises PT on Theravance to $35

    Benzinga
  45. Notable Put Options Activity in Theravance

    Benzinga
  46. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 10,000 Shares

    GuruFocus
Trading Center